Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 12, 2014, Pages 2726-2735

  Branca, Caterina ^a,b   Wisely, Elena V ^c   Hartman, Lauren K ^a   Caccamo, Antonella ^a,d   Oddo, Salvatore ^a,e  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

APP; A ; Tangles; Tau; Blockers

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; TAU PROTEIN; PROPANOLAMINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MODEL; DRUG STRUCTURE; FEMALE; MORRIS WATER MAZE TEST; MOUSE; NEUROPATHOLOGY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR BLOCKING; SENILE PLAQUE; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; COGNITION; DISEASE COURSE; DRUG EFFECTS; HIPPOCAMPUS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PSYCHOLOGY; TRANSGENIC MOUSE;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; COGNITION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; MALE; MICE, TRANSGENIC; PHOSPHORYLATION; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; TAU PROTEINS;

EID: 84911400600     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.06.011     Document Type: Article

References (59)

1. Ameredes B.T. Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle. Front. Biosci. (Schol Ed) 2011, 3:643-654.
2. Antunes M., Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn. Process 2012, 13:93-110.
3. Artero S., Tierney M.C., Touchon J., Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr. Scand. 2003, 107:390-393.
4. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
5. Caccamo A., Magri A., Medina D.X., Wisely E.V., Lopez-Aranda M.F., Silva A.J., Oddo S. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 2013, 12:370-380.
6. Caccamo A., Medina D.X., Oddo S. Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: implications for aging, stress and TDP-43 proteinopathies. J.Neurosci. 2013, 33:906-913.
7. Chruscinski A.J., Rohrer D.K., Schauble E., Desai K.H., Bernstein D., Kobilka B.K. Targeted disruption of the beta2 adrenergic receptor gene. J.Biol. Chem. 1999, 274:16694-16700.
8. Connor S.A., Wang Y.T., Nguyen P.V. Activation of {beta}-adrenergic receptors facilitates heterosynaptic translation-dependent long-term potentiation. J.Physiol. 2011, 589(Pt 17):4321-4340.
9. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J.Neurochem. 2010, 113:649-660.
10. Cowansage K.K., LeDoux J.E., Monfils M.H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol. 2010, 3:12-29.
11. Csiszar A., Tucsek Z., Toth P., Sosnowska D., Gautam T., Koller A., Deak F., Sonntag W.E., Ungvari Z. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H1120-H1130.
12. Daly C.J., McGrath J.C. Previously unsuspected widespread cellular and tissue distribution of beta-adrenoceptors and its relevance to drug action. Trends Pharmacol. Sci. 2011, 32:219-226.
13. Feany M.B., Dickson D.W. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. 1996, 40:139-148.
14. Flores O., Nunez H., Perez H., Morgan C., Soto-Moyano R., Valladares L., Burgos H., Olivares R., Hernandez A. Beta-adrenoceptor blockade depresses molecular and functional plasticities in the rat neocortex. Brain Res. Bull 2010, 82:284-288.
15. Gelinas J.N., Nguyen P.V. Beta-adrenergic receptor activation facilitates induction of a protein synthesis-dependent late phase of long-term potentiation. J.Neurosci. 2005, 25:3294-3303.
16. Gibbs M.E., Hutchinson D.S., Summers R.J. Noradrenaline release in the locus coeruleus modulates memory formation and consolidation; roles for alpha- and beta-adrenergic receptors. Neuroscience 2010, 170:1209-1222.
17. Gibbs M.E., Summers R.J. Role of adrenoceptor subtypes in memory consolidation. Prog. Neurobiol. 2002, 67:345-391.
18. Gleeson L.C., Ryan K.J., Griffin E.W., Connor T.J., Harkin A. The beta2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. Brain Behav. Immun. 2010, 24:1354-1361.
19. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57:846-851.
20. Insel P.A. β(2)-Adrenergic receptor polymorphisms and signaling: do variants influence the "memory" of receptor activation?. Sci. Signal 2011, 4:pe37.
21. Joiner M.L., Lise M.F., Yuen E.Y., Kam A.Y., Zhang M., Hall D.D., Malik Z.A., Qian H., Chen Y., Ulrich J.D., Burette A.C., Weinberg R.J., Law P.Y., El-Husseini A., Yan Z., Hell J.W. Assembly of a beta2-adrenergic receptor-GluR1 signalling complex for localized cAMP signalling. EMBO J. 2010, 29:482-495.
22. Juric D.M., Loncar D., Carman-Krzan M. Noradrenergic stimulation of BDNF synthesis in astrocytes: mediation via alpha1- and beta1/beta2-adrenergic receptors. Neurochem. Int. 2008, 52:297-306.
23. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 2006, 63:686-692.
24. Kolinski M., Plazinska A., Jozwiak K. Recent progress in understanding of structure, ligand interactions and the mechanism of activation of the beta(2)-adrenergic receptor. Curr. Med. Chem. 2012, 19:1155-1163.
25. Li S., Jin M., Zhang D., Yang T., Koeglsperger T., Fu H., Selkoe D.J. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 2013, 77:929-941.
26. Lin Y.W., Min M.Y., Chiu T.H., Yang H.W. Enhancement of associative long-term potentiation by activation of beta-adrenergic receptors at CA1 synapses in rat hippocampal slices. J.Neurosci. 2003, 23:4173-4181.
27. Majumder S., Caccamo A., Medina D.X., Benavides A.D., Javors M.A., Kraig E., Strong R., Richardson A., Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012, 11:326-335.
28. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011, 6:e25416.
29. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:4245-4249.
30. McIntyre C.K., McGaugh J.L., Williams C.L. Interacting brain systems modulate memory consolidation. Neurosci. Biobehav. Rev. 2012, 36:1750-1762.
31. Medina D.X., Orr M.E., Oddo S. Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol. Aging 2014, 35:79-87.
32. Mizushima N., Noda T., Yoshimori T., Tanaka Y., Ishii T., George M.D., Klionsky D.J., Ohsumi M., Ohsumi Y. Aprotein conjugation system essential for autophagy. Nature 1998, 395:395-398.
33. Nelson L., Gard P., Tabet N. Hypertension and inflammation in Alzheimer's disease: close partners in disease development and progression!. J.Alzheimers Dis. 2014, 41:331-343.
34. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., Song M., Xiong J., Bai Y., Pei G. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006, 12:1390-1396.
35. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
36. Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J.Neurosci. 2008, 28:12163-12175.
37. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J.Biol. Chem. 2006, 281:39413-39423.
38. Orr M.E., Salinas A., Buffenstein R., Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol. Aging 2014, 35:1233-1242.
39. Perry R.J., Hodges J.R. Attention and executive deficits in Alzheimer's disease. A critical review. Brain 1999, 122(Pt 3):383-404.
40. Qian H., Matt L., Zhang M., Nguyen M., Patriarchi T., Koval O.M., Anderson M.E., He K., Lee H.K., Hell J.W. β2-Adrenergic receptor supports prolonged theta tetanus-induced LTP. J.Neurophysiol. 2012, 107:2703-2712.
41. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
42. Roozendaal B., Castello N.A., Vedana G., Barsegyan A., McGaugh J.L. Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol. Learn Mem. 2008, 90:576-579.
43. Sato S., Shirato K., Tachiyashiki K., Imaizumi K. Muscle plasticity and beta(2)-adrenergic receptors: adaptive responses of beta(2)-adrenergic receptor expression to muscle hypertrophy and atrophy. J.Biomed. Biotechnol. 2011, 2011:729598.
44. Selvam B., Wereszczynski J., Tikhonova I.G. Comparison of dynamics of extracellular accesses to the beta(1) and beta(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity. Chem. Biol. Drug Des. 2012, 80:215-226.
45. Summerhill S., Stroud T., Nagendra R., Perros-Huguet C., Trevethick M. Acell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J.Pharmacol. Toxicol. Methods 2008, 58:189-197.
46. Thies W., Bleiler L., Alzheimer's A. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208-245.
47. Thomas M.J., Moody T.D., Makhinson M., O'Dell T.J. Activity-dependent beta-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron 1996, 17:475-482.
48. Walling S.G., Harley C.W. Locus ceruleus activation initiates delayed synaptic potentiation of perforant path input to the dentate gyrus in awake rats: a novel beta-adrenergic- and protein synthesis-dependent mammalian plasticity mechanism. J.Neurosci. 2004, 24:598-604.
49. Wang D., Fu Q., Zhou Y., Xu B., Shi Q., Igwe B., Matt L., Hell J.W., Wisely E.V., Oddo S., Xiang Y.K. β2-Adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J.Biol. Chem. 2013, 288:10298-10307.
50. Wang D., Govindaiah G., Liu R., De Arcangelis V., Cox C.L., Xiang Y.K. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 2010, 24:3511-3521.
51. Wang D., Yuen E.Y., Zhou Y., Yan Z., Xiang Y.K. Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J.Biol. Chem. 2011, 286:31852-31863.
52. Wang Q.W., Rowan M.J., Anwyl R. Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol. Aging 2009, 30:1608-1613.
53. Welsh K.A., Butters N., Hughes J.P., Mohs R.C., Heyman A. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch. Neurol. 1992, 49:448-452.
54. Wisely E.V., Xiang Y.K., Oddo S. Genetic suppression of beta2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. Hum. Mol. Genet. 2014, 23:4024-4034.
55. Wiysonge C.S., Bradley H.A., Volmink J., Mayosi B.M., Mbewu A., Opie L.H. Beta-blockers for hypertension. Cochrane Database Syst. Rev. 2012, 11:CD002003.
56. Woo A.Y., Xiao R.P. β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol. Sin. 2012, 33:335-341.
57. Yu J.T., Tan L., Ou J.R., Zhu J.X., Liu K., Song J.H., Sun Y.P. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Brain Res. 2008, 1210:216-222.
58. Yu N.N., Wang X.X., Yu J.T., Wang N.D., Lu R.C., Miao D., Tian Y., Tan L. Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production. Brain Res. 2010, 1317:305-310.
59. Zhou H.C., Sun Y.Y., Cai W., He X.T., Yi F., Li B.M., Zhang X.H. Activation of beta2-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats. Learn Mem. 2013, 20:274-284.